{"id":"NCT00313846","sponsor":"Purdue Pharma LP","briefTitle":"Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of the Buprenorphine Transdermal Delivery System in Subjects With Moderate to Severe Osteoarthritic Pain of Hip or Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-04","primaryCompletion":"2004-06","completion":"2004-06","firstPosted":"2006-04-12","resultsPosted":"2010-09-28","lastUpdate":"2012-09-03"},"enrollment":529,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":["Butransâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BTDS","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe osteoarthritis pain of the hip and knee currently treated with oral opioids. The double-blind treatment intervention duration is 4 weeks during which time supplemental analgesic medication (acetaminophen) will be provided to all subjects in addition to study drug.","primaryOutcome":{"measure":"The Time (Days) From First Administration of Double-blind Treatment to the Development of Inadequate Analgesia at the Primary Osteoarthritis Pain Site.","timeFrame":"Double-blind phase ( 28 days): reaching \"inadequate analgesia\" on any 2 days of the 7-day dosing periods","effectByArm":[{"arm":"Double-blind Placebo","deltaMin":12.3,"sd":0.77},{"arm":"Double-blind BTDS","deltaMin":17.2,"sd":0.89}],"pValues":[{"comp":"OG000 vs OG001","p":".0026"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":162},"commonTop":["Nausea","Headache","Dizziness","Constipation","Somnolence"]}}